Vivacelle Bio is a clinical-stage biopharmaceutical company focused on transforming the treatment of shock and other life-threatening conditions through its groundbreaking phospholipid nanotechnology. The company’s lead product candidates are designed to restore vascular function and improve survival in patients experiencing septic shock, hemorrhagic shock, and related critical illnesses. By leveraging innovative lipid-based formulations, Vivacelle Bio is pioneering a new approach to critical care medicine, with the goal of saving lives and redefining emergency treatment protocols worldwide.